Q&A cata­log for importers and dis­tri­bu­tors of medi­cal devices

Importers and dis­tri­bu­tors may have the obli­ga­ti­ons of manu­fac­tu­r­ers in accordance with Artic­le 16 MDR in cer­tain cases. This is the case, for ins­tance, when a dis­tri­bu­tor or importer makes a medi­cal device available on the mar­ket under its own name, chan­ges the inten­ded pur­po­se of the medi­cal device, or makes other chan­ges to the device that could affect its com­pli­ance with appli­ca­ble legal requi­re­ments. For details, see our pre­vious news.

Artic­le 16(2) MDR spe­ci­fies the cases in which cer­tain acti­vi­ties of importers and dis­tri­bu­tors are not con­side­red to be chan­ges to a device within the mea­ning of Artic­le 16(1)© that could affect the com­pli­ance of the device with the appli­ca­ble requi­re­ments. In such cases, importers and dis­tri­bu­tors do not assu­me the manu­fac­tu­rer’s obli­ga­ti­ons.

The­se cases involve:

  • (a) pro­vi­si­on of infor­ma­ti­on, trans­la­ti­on of the infor­ma­ti­on pro­vi­ded by the manu­fac­tu­rer, inclu­ding the ins­truc­tions for use (IFU), neces­sa­ry for pla­cing the device on the mar­ket in the Mem­ber Sta­te (rela­be­l­ing).
  • (b) chan­ges to the outer pack­a­ging of a device alre­a­dy pla­ced on the mar­ket which are neces­sa­ry for pla­cing the device on the mar­ket in the Mem­ber Sta­te con­cer­ned (repack­a­ging).

The importers and dis­tri­bu­tors refer­red to in Artic­le 16(2) are sub­ject to obli­ga­ti­ons dif­fe­rent from than tho­se of the manu­fac­tu­rer descri­bed in Artic­le 16(3) and (4) MDR.

Gui­dance docu­ment MDCG 2021–26

The MDCG 2021–26 Gui­dance Docu­ment (PDF) addres­ses rele­vant aspects for the eco­no­mic ope­ra­tors car­ry­ing out any of the acti­vi­ties refer­red to in Artic­le 16(2)(a) and (b) of the Regu­la­ti­ons, i.e. rela­be­l­ing and/or repack­a­ging of devices.

It pro­vi­des assis­tance and ans­wers to the fol­lo­wing questions:

  • Do Artic­les 16(2), (3) and (43) app­ly only to importers and dis­tri­bu­tors or also to “other natu­ral or legal per­sons” as men­tio­ned in Artic­le 16(1)?
  • Do Artic­le 16(3) and (4) MDR app­ly to “lega­cy devices”?
  • For the acti­vi­ties refer­red to in Artic­le 16(2)(a) and (b), what is meant by ‘neces­sa­ry to mar­ket the device’ in the Mem­ber Sta­te question?
  • Does the divi­si­on of lar­ge quan­ti­ties of devices in ship­ping con­tai­ners into smal­ler quan­ti­ties of devices in packa­ges or indi­vi­du­al units fall under Artic­le 16(2)?
  • What infor­ma­ti­on should be pro­vi­ded to the manu­fac­tu­rer pur­su­ant to Artic­le 16(4)?
  • What infor­ma­ti­on is must be repor­ted to the com­pe­tent aut­ho­ri­ty pur­su­ant to Artic­le 16(4)?
  • Must the manu­fac­tu­rer and the com­pe­tent aut­ho­ri­ty be noti­fied each time an indi­vi­du­al device or batch of devices is rela­be­led or repackaged?
  • Under what con­di­ti­ons should a noti­fi­ca­ti­on sent to the manu­fac­tu­rer and the com­pe­tent aut­ho­ri­ty be car­ri­ed out?
  • Must the manu­fac­tu­rer and the com­pe­tent aut­ho­ri­ty be noti­fied when an importer or dis­tri­bu­tor stops rela­be­l­ing and/or repackaging?
  • What noti­fied bodies can importers and dis­tri­bu­tors turn to for the
  • cer­ti­fi­ca­ti­on pur­su­ant to Artic­le 16(4)?
  • Is rela­be­l­ing and/or repack­a­ging of Class I and Class A in vitro dia­gno­stic medi­cal devices also sub­ject to review by a noti­fied body as defi­ned in Artic­le 16(4)?
  • Can the importer or dis­tri­bu­tor pro­vi­de addi­tio­nal batch num­ber infor­ma­ti­on while rela­be­l­ing and/or repackaging?
  • If the ins­truc­tions for use are trans­la­ted, is it neces­sa­ry to keep the ori­gi­nal ver­si­on of the ins­truc­tions for use in the packaging?
  • Do jobs that requi­re rela­be­l­ing and/or repack­a­ging acti­vi­ties pur­su­ant to
  • Artic­le 16(2) of the Regu­la­ti­on, com­ply with any obli­ga­ti­ons regar­ding tracea­bi­li­ty and uni­que device iden­ti­fi­ca­ti­on (UDI11)?

Prac­ti­cal use of the Gui­dance Docu­ment and recom­men­ded action

From this, it can be seen that the MDCG alre­a­dy addres­ses in gre­at detail poten­ti­al com­pre­hen­si­on pro­blems and any issues in light of Artic­le 16 MDR. For importers and dis­tri­bu­tors, the MDC­G’s recom­men­da­ti­ons should the­r­e­fo­re be a valuable aid in posi­tio­ning them­sel­ves to be MDR-compliant.

Nevert­hel­ess, it remains essen­ti­al to careful­ly check the spe­ci­fic rela­be­l­ing or repack­a­ging for MDR com­pli­ance on a case-by-case basis. Ulti­m­ate­ly, this is the only way to pre­vent the respec­ti­ve pro­cess from (unin­ten­tio­nal­ly) resul­ting in manu­fac­tu­rer obli­ga­ti­ons and the asso­cia­ted lia­bi­li­ty risks for the importer or distributor.

back

Stay up-to-date

We use your e-mail address exclusively for sending our newsletter. You have the right to revoke your consent at any time with effect for the future. For further information, please refer to our privacy policy.